Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Diabetic Nephropathy

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration...

Antihypertensive Drugs: Direct Renin Inhibitors

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...

Heart Failure V: Medical Management

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...

Type II Diabetes II: Pathophysiology

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Personalized management of angina and heart failure in clinical practice in the Middle East: a narrative review.

Journal of comparative effectiveness research·2026

Same author

Effect of collection timing on selectivity index in unstimulated adrenal venous sampling: discovery and validation.

Hypertension research : official journal of the Japanese Society of Hypertension·2026

Same author

Correction to: Cost-Consequences of Adding Gliclazide Modified Release to Metformin in Patients with Uncontrolled Type 2 Diabetes in the United Arab Emirates.

Advances in therapy·2025

Same author

Cost-Consequences of Adding Gliclazide Modified Release to Metformin in Patients with Uncontrolled Type 2 Diabetes in the United Arab Emirates.

Advances in therapy·2025

Same author

Disease burden, comorbidities, and treatment patterns of patients with multiple myeloma in Dubai: a retrospective analysis of the Dubai real-world claims database.

Current medical research and opinion·2025

Same author

Two-Decade Trends in MASLD and Its Complications in the Middle East and North Africa (2010-2021).

Liver international : official journal of the International Association for the Study of the Liver·2025

Search research articles

Related Experiment Video

Updated: Apr 23, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Beyond Traditional Silos: An Integrated Framework Leveraging Novel Pathways for Reducing Cardio-renal Risk in Type 2

Hani M Sabbour¹, Mohamad Hassanein^2,3, Mohamed Farghaly⁴

¹Department of Cardiology, Mediclinic Hospital, Abu Dhabi, UAE.

Current Diabetes Reviews

|June 2, 2025

Summary

Diabetes and chronic kidney disease (CKD) significantly increase cardiovascular disease risk. Experts identified treatment gaps for managing these interconnected conditions in the Middle East.

Keywords:

Chronic kidney disease cardiovascular disease diabetes mellitus finerenone mineralocorticoid receptor antagonist renin-angiotensin system sodium-glucose co-transporter-2 inhibitors

More Related Videos

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Published on: May 10, 2024

Related Experiment Videos

Last Updated: Apr 23, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Published on: May 10, 2024

Area of Science:

Cardiology
Nephrology
Diabetology

Background:

Diabetes mellitus is a primary driver of chronic kidney disease (CKD) progression, increasing end-stage renal disease risk.
CKD patients face heightened cardiovascular disease (CVD) risks, including coronary artery disease, heart failure, and arrhythmias, due to the cardiorenal connection.

Purpose of the Study:

To review the epidemiology, pathophysiology, diagnosis, and treatment of CKD in diabetic patients.
To identify treatment gaps and unmet needs for managing the cardiorenal connection in the Middle East.
To discuss the roles of clinical specialties in simplifying patient journeys.

Main Methods:

An online expert panel of cardiologists, nephrologists, and diabetologists convened in November 2021.
A comprehensive review of current literature on diabetes, CKD, and CVD was conducted.
Discussion focused on treatment options to reduce morbidity and mortality in high-risk populations.

Main Results:

Diabetes significantly accelerates kidney function decline and is linked to increased CVD risk.
The cardiorenal connection exacerbates complications in patients with diabetes and CKD.
Identified treatment gaps require multidisciplinary approaches for optimal patient care.

Conclusions:

Integrated management strategies are crucial for patients with diabetes, CKD, and CVD.
Simplifying the patient journey through coordinated care can improve outcomes.
Addressing unmet needs in the Middle East requires a focus on the cardiorenal nexus.